samotolisib   Click here for help

GtoPdb Ligand ID: 8918

Synonyms: example 1 [US8440829] | LY-3023414 | LY3023414
Compound class: Synthetic organic
Comment: samotolisib (LY3023414) is a dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the serine/threonine kinase mTOR ( mechanistic target of rapamycin) [1], with potential antineoplastic activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 82.17
Molecular weight 406.2
XLogP 1.63
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(Cn1c(=O)n(c2c1c1cc(ccc1nc2)c1cncc(c1)C(O)(C)C)C)C
Isomeric SMILES CO[C@H](Cn1c(=O)n(c2c1c1cc(ccc1nc2)c1cncc(c1)C(O)(C)C)C)C
InChI InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1
InChI Key ACCFLVVUVBJNGT-AWEZNQCLSA-N
No information available.
Summary of Clinical Use Click here for help
LY3023414 has progressed to Phase 2evaluation its potential to treat several solid tumour types, including recurrent endometrial cancer, metastatic prostate cancer and metastatic non-small cell lung cancer (NSCLC), and non-Hodgkin's lymphoma. Click here to link to ClinicalTrials.gov's full list of LY3023414 trials.